Not currently recruiting at UCLA
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Torrance, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Charity Huang
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Charity Huang
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 4 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)
- ID
- NCT06119581
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1016 study participants
- Last Updated